15.07.2020 • NewsMerckDede WillamsDrug Development

Merck Opens Drug Development Center in Shanghai

Under the name M Lab, Germany’s Merck has opened a new collaborative drug development center in Pudong, Shanghai, China. The facility with lab space of around 10,000 m2 is the largest of the pharmaceutical, chemicals and life science group’s nine such centers worldwide and is located in the heart of Shanghai’s biomedical sciences and research community.

Merck’s concept provides what it says are customizable solutions to help advance drug development, including pilot scale and process development support labs that offer non-GMP space. In the labs, customers can explore ideas, learn innovative techniques and work side-by-side with the German company’s scientists and engineers on problem solving and also participate in hands-on training, formal bioprocessing educational courses and experiments.

One of the focuses of the Shanghai center is on lab management software, with a digital platform that improves efficiency and processes by automating workflows and connecting lab instruments via the cloud.

Also part of the center is a customized cell culture media facility designed to develop cell culture media that can be used to produce biopharmaceuticals and for non-GMP pilot production.

Separately, a solid dose formulation facility is available to test whether drugs in tablet, capsule or powder form contain high quality excipients and active pharmaceutical ingredients.  (APIs), while a new end-to-end solutions GMP manufacturing facility will be able to offer CDMO services to Merck’s customers in China and Asia Pacific.

With development of vaccines for Covid-19 moving forward at record speeds, vaccine makers are increasingly looking for CDMOs that have the capability to quickly provide the needed manufacturing capability. Merck’s manufacturing services outfit could take in billions of dollars in revenue through assisting certain players with scale-up, Jefferies analyst Brandon Couillard said in a note to clients. 

The German company is currently working with more than 200 groups developing COVID-19 vaccines and drugs, including the UK’s Oxford University and Baylor University and Oxford University in the US state of Texas. Couillard said his team quantifies the overall market opportunity for Covid products at roughly $4-5 billion.

Merck has opened a new collaborative drug development center in Shanghai,...
Merck has opened a new collaborative drug development center in Shanghai, China. With a lab space of around 10,000 m2, this is the largest of nine such centers. The German group is now assisting 200 companies or institutes working on Covid-19 vaccines. (c) Merck

Company

Merck KGaA

Frankfurter Str. 250
64293 Darmstadt
Germany

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.